Dysphagia Management Industry Analysis in the United Kingdom
Analyzing Dysphagia Management Demand Outlook in the United Kingdom by Drugs and Feeding Tubes, 2023 to 2033
Demand for Dysphagia Management Supplements, including Powder and Gel Thickeners, Rises as Patients Understand the Urgency of Curing the Painful Condition across the United Kingdom
United Kingdom Dysphagia Management Industry Outlook for (2023 and 2033)
The United Kingdom's dysphagia management business revenue is expected to increase from US$ 232.4 million in 2023 to US$ 293.3 million by 2033. Over the forecast period, demand for dysphagia management products across the United Kingdom is predicted to rise at a CAGR of 2.4%. Total revenue from the dysphagia management business in the United Kingdom totaled US$ 228.2 million at the end of 2022.
The rising prevalence of neurological disorders, structural abnormalities, or other medical conditions is expected to push the cases of dysphagia worldwide. The growing need for treating this condition is expected to drive the demand for dysphagia management solutions.
Key companies are focusing on developing new drugs and medical devices for the management of swallowing disorders in the United Kingdom. This is expected to foster growth in the United Kingdom’s dysphagia management business.
Other Factors Driving Dysphagia Management Demand in the United Kingdom-
Development of cutting-edge dysphagia management tools in the United Kingdom
Easy availability of dysphagia treatment and services in the United Kingdom
Favorable government support
Rising health awareness and expansion of healthcare infrastructure
Attributes
Key Insights
Dysphagia Management Business Size in the United Kingdom (2022)
US$ 228.2 million
Estimated United Kingdom Dysphagia Management Business Revenue (2023)
US$ 232.4 million
Projected United Kingdom Dysphagia Management Business Revenue (2033)
US$ 293.3 million
Value-based CAGR (2023 to 2033)
2.4%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 United Kingdom Dysphagia Management Business Vs. 2033 to 2033
The United Kingdom dysphagia management business recorded a CAGR of 1.2% from 2018 to 2022. Total revenue in the country reached US$ 228.2 million at the end of 2022. Over the assessment period, dysphagia management demand in the United Kingdom is predicted to increase at a 2.4% CAGR.
Historical CAGR (2018 to 2022)
1.2%
Forecast CAGR (2023 to 2033)
2.4%
Several factors are expected to spur growth in the United Kingdom's dysphagia management business. These include the rising prevalence of dysphagia and other swallowing disorders, growing health awareness, and increasing spending on swallowing disorder treatment in the United Kingdom.
Dysphagia is especially prevalent among the geriatric population. For instance, studies suggest that dysphagia is thought to affect around 4 million people in the United Kingdom. This will continue to drive demand for dysphagia management solutions.
Certain chronic health conditions, such as gastroesophageal reflux disease (GERD), muscular dystrophy, and scleroderma, can result in dysphagia. Hence, the increasing prevalence of these conditions is expected to create lucrative opportunities for dysphagia management companies.
In the United Kingdom, the National Health Service (NHS) and the Department of Health and Social Care are playing a key role in tackling the burden of swallowing disorders, including dysphagia. This will positively impact overall dysphagia management product sales.
For instance, the Speech and Language Therapy service at Sheffield Teaching Hospital’s NHS Foundation Trust launched a novel bite-sized online learning resource to improve the understanding of dysphagia. These initiatives are likely to boost dysphagia management solution sales.
Primary Factors Propelling United Kingdom’s Dysphagia Management Demand
Dysphagia can lead to feelings of frustration, embarrassment, and isolation. Difficulty in eating and drinking can result in a reduced quality of life, impacting an individual's social interactions and overall happiness. Hence, the importance of dysphagia management is proliferating.
Dysphagia is commonly seen in patients with neurological disorders and stroke. The main symptoms of dysphagia in neurological disorders are delayed oral transit and difficulties in bolus formation, among others. To treat this condition, patients are expected to opt for dysphagia management solutions, including PPIs, feeding devices, and nutritional supplements.
To avoid difficulties in swallowing solid foods, consumers are showing interest in dysphagia supplement products such as powder thickeners and gel thickeners. The increasing adoption of these supplements will boost the total dysphagia management business revenue.
Greater awareness about dysphagia means that healthcare professionals are more likely to identify and diagnose swallowing disorders at an early stage. This can lead to quicker interventions and better outcomes for individuals with dysphagia.
The recognition of dysphagia as a significant health concern can drive research and innovation in the field. This can lead to the development of new diagnostic tools, therapies, and products designed to improve the quality of life for individuals with dysphagia.
The increasing awareness of dysphagia in the United Kingdom and emerging countries is a positive development that can lead to better healthcare outcomes and increased access to dysphagia management services. It will also create new opportunities for innovation and collaboration in the field of dysphagia management.
Find your sweet spots for generating winning opportunities in this market.
Restrictive Factors in the United Kingdom Dysphagia Management Business
The usage of equipment in high-risk anatomical regions, including the anterior neck, requires specific clearance from the Food & Drug Administration (FDA). The general clearance for neuromuscular stimulation/reeducation is not sufficient. This is acting as an impediment for companies.
Contrary to other body parts, the FDA has always issued a warning label for the use of neuromuscular electrical stimulation (NMES) on the anterior neck. This is because there is a chance of severe harm or death while utilizing general clearance NMES devices and supplies on the neck. This factor is limiting the growth of the target business to a certain extent.
Long-term use of dysphagia drugs such as proton pump inhibitors is associated with certain threats, such as the increased risk of hip bone fracture. This is due to the decreased absorption of calcium and iron and the risk of opportunistic infections with S. pneumonia and C. defficile owing to diminished natural gut flora.
The use of nasogastric tubes or PEG tubes can cause irritation to the throat, which leads to severe discomfort. Long-term administration of such tubes can cause abdominal cramping, abdominal swelling, diarrhea, nausea, vomiting, and regurgitation of food and medicines.
Dysphagia drugs, such as proton pump inhibitors (PPIs) and H2 blockers, are expected to be commonly used to treat GERD, a condition that can cause dysphagia. While these drugs are generally safe and effective, they can cause side effects such as headache, diarrhea, and abdominal pain.
In a handful of cases, long-term use of PPIs has been linked to an increased risk of certain health conditions, such as bone fractures, kidney disease, and other infections. Hence, the side effects of PPIs and feeding tubes can limit their usage, thereby hampering the expansion of the target business.
Comparative View of Adjacent Businesses
The United Kingdom's dysphagia management business is expected to be impacted by the peer or tangential businesses in the healthcare division. This includes businesses such as proton pump inhibitors and throat sprays market. On analysis of these related sectors, the report has detected profound insights that will be helpful for developing unique differentiating strategies to pursue growth and opportunity.
United Kingdom Dysphagia Management Demand Outlook:
Attributes
United Kingdom Dysphagia Management Demand Outlook
CAGR (2023 to 2033)
2.4%
Value (2023)
US$ 293.3 million
Growth Factor
The growing prevalence of dysphagia is expected to drive the demand for dysphagia management products, including drugs and feeding tubes.
Key Trend
The development of new dysphagia therapies in Britain is a key trend in the dysphagia management business.
Proton Pump Inhibitor Sales Forecast:
Attributes
Proton Pump Inhibitor Sales Forecast
CAGR (2023 to 2033)
5.2%
Value (2023)
US$ 3.0 billion
Growth Factor
Growing demand for effective acid-suppressing medication is anticipated to bolster proton pump inhibitor sales.
Key Trend
The rising prevalence of gastrointestinal disorders and the development of new PPIs are key trends impacting sales.
Throat Spray Industry Analysis:
Attributes
Throat Spray Industry Analysis
CAGR (2023 to 2033)
2.1%
Value (2023)
US$ 484 million
Growth Factor
The rising prevalence of upper respiratory tract infections is expected to drive demand for throat sprays.
Key Trend
Increasing promotional and awareness campaigns will create growth prospects for throat spray manufacturers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
State-wise Insights
Growth Outlook by Key States
States
Value CAGR
Greater London
1.9%
West Midlands
2.8%
Greater Manchester
3.6%
West Yorkshire
5.7%
Glasgow
2.6%
Rising Prevalence of Dysphagia Driving Demand in Greater London
As per the latest report, Greater London is projected to remain a lucrative pocket for dysphagia management companies across England. Over the forecast period, the demand for dysphagia management solutions in Greater London is projected to rise at a 1.9% CAGR.
By 2033, Greater London’s dysphagia management business revenue is anticipated to reach US$ 46.8 million. It will likely hold a share of 21.1% in England by the end of 2033. This is attributable to the rising incidence of dysphagia.
Dysphagia often results from underlying medical conditions such as stroke, Parkinson's disease, and dementia. Greater London's diverse and growing population can experience a higher prevalence of these conditions, driving the demand for dysphagia management.
Awareness among healthcare professionals and the public regarding the diagnosis and management of dysphagia is also growing rapidly in Greater London. This can lead to early diagnosis and intervention, increasing the need for related services.
Presence of Rehabilitation Centers Boosting Revenue in West Midlands
West Midlands is projected to experience a CAGR of 2.8% during the forecast period. Total dysphagia management sales in the West Midlands are set to reach US$ 23.0 million by 2033. The presence of rehabilitation centers and long-term care facilities in the region can drive the demand for dysphagia management products and services, as these institutions often cater to patients with swallowing difficulties.
The presence of well-established healthcare infrastructure, including hospitals, clinics, and skilled healthcare professionals specializing in dysphagia management, can encourage patients to seek treatment across the region. This will boost overall revenue in the West Midlands through 2033.
Category-wise Insights
The section below shows the drugs segment witnessing a higher CAGR of 5.2% during the assessment period. Based on indication, the oropharyngeal dysphagia category is expected to hold a prominent value share by 2033, exhibiting a CAGR of 1.5%. By distribution channel, the hospital pharmacies segment will retain its dominance in the United Kingdom, thriving at a 1.2% CAGR through 2033.
Proton Pump Inhibitors to Witness High Demand in the United Kingdom
Growth Outlook by Key Product
Product
Value CAGR
Drugs (Proton Pump Inhibitors)
5.2%
Feeding Tubes
1.6%
Nutritional Solutions
2.2%
Devices
4.1%
Based on product, the drugs (proton pump inhibitors) segment is expected to thrive at a 5.2% CAGR during the forecast period. As a result, dysphagia management companies looking to boost their revenue will likely shift their focus on offering novel and effective proton pump inhibitors.
Proton pump inhibitors (PPIs) are primarily prescribed to reduce stomach acid production. By managing conditions such as GERD and acid reflux, which are common causes of dysphagia, PPIs help alleviate the symptoms and underlying causes of swallowing difficulties. This, in turn, leads to better dysphagia management.
PPIs can also help reduce the discomfort associated with acid-related conditions, making it easier for individuals with dysphagia to eat and swallow. This improved comfort can lead to better patient compliance with dysphagia management plans.
Oropharyngeal Dysphagia to Generate Maximum Revenue for Companies
Growth Outlook by Indication
Indication
Value CAGR
Oropharyngeal Dysphagia
1.5%
Esophageal Dysphagia
5.2%
As per the latest dysphagia management industry analysis, the oropharyngeal dysphagia segment is set to create lucrative revenue generation for dysphagia management companies. This is attributed to the rising prevalence of oropharyngeal dysphagia in the United Kingdom.
The oropharyngeal dysphagia segment is anticipated to expand at a 1.5% CAGR during the forecast period. It is expected to total US$ 218.2 million by 2033, accounting for a value share of 74.4% in the United Kingdom.
Oropharyngeal dysphagia patients frequently require speech therapy and rehabilitation to improve their swallowing function. This drives the demand for speech therapists, drugs, medical devices, and rehabilitation facilities, which are key components of the dysphagia management business.
Oropharyngeal dysphagia treatment plans are often tailored to the individual's specific needs and the underlying causes of the condition. This personalization of care can result in a variety of management options and interventions, including dietary modifications and exercises, all of which contribute to revenue growth.
Hospital Pharmacies to Retain Their Dominance Through 2033
Growth Outlook by Key End-user
Application
Value CAGR
Hospital Pharmacies
1.2%
Retail Pharmacies
1.8%
Drug Stores
2.9%
Specialty Clinics
5.1%
Based on end-users, the hospital pharmacies segment is projected to expand at a 1.2% CAGR during the assessment period. As per the latest analysis of dysphagia management in the United Kingdom, the target segment will likely hold a share of about 36.2% by 2033.
Hospital pharmacies are responsible for dispensing medications to patients within the hospital. For dysphagia patients, this can include specialized oral medications or alternative routes of administration, such as enteral feeding through feeding tubes. The availability and proper management of these medications are essential for effective dysphagia treatment.
Competitive Landscape
Strategic partnerships are a priority for leading dysphagia management companies in the United Kingdom as they work to create new product lines and expand their global consumer base. Key players are also investing heavily in research and development to develop cutting-edge dysphagia management tools in the United Kingdom.
Recent Developments in the United Kingdom Dysphagia Management Business-
In October 2022, the United Kingdom-based company Phagenesis Ltd. launched the Phageneyx Neurostimulation System in the United States. The new system uses pharyngeal electrical stimulation to treat people with dysphagia.
In October 2022, Eisai and Cogstate expanded their agreement for the global development and commercialization of digital cognitive assessment technologies.
In December 2022, Astellas, Eisai, Daiichi Sankyo, and Takeda agreed to collaborate to reduce the environmental burden in the field of pharmaceutical packaging.
Scope of the United Kingdom Dysphagia Management Business Report
Attribute
Details
Estimated Value (2023)
US$ 232.4 million
Expected Value (2033)
US$ 293.3 million
Anticipated Growth Rate (2023 to 2033)
2.4% CAGR
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Industry Analysis
US$ million for Value
Key Regions Covered
England, Wales, Scotland, Northern Ireland
Key States Covered
Greater London, West Midlands, Greater Manchester, West Yorkshire, Rest of England, Cardiff, Swansea, Rhondda Cynon Taf, Carmarthenshire, Rest of Wales, Glasgow, Edinburgh, Aberdeen, Lanarkshire, Rest of Scotland, Antrim, Armagh, Down, Fermanagh, Rest of Northern Ireland
Key Segments Covered
Product, Indication, Distribution Channel, and Region
United Kingdom Dysphagia Management Industry Analysis by Category
By Product:
Drugs (Proton Pump Inhibitors)
Feeding Tubes
Naso-gastric Tubes
PEG Tubes
Nutritional Solutions
Thickeners
Beverages
Purees
Devices
Medical Cups
Neuromuscular Electrical Stimulation (NEMS)
Tactile-thermal Stimulation (TTS)
Pharyngeal Electrical Stimulation (PES)
By Indication:
Oropharyngeal Dysphagia
Esophageal Dysphagia
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Specialty Clinics
By Country:
England
Wales
Scotland
Northern Ireland
Frequently Asked Questions
How big is the dysphagia management business in the United Kingdom?
Total revenue is set to reach US$ 232.4 million in 2023.
What is the expected size of the target business in 2033?
The target business is expected to be valued at US$ 293.3 million by 2033.
Which product segment will witness high growth in the United Kingdom?
The drug segment is expected to witness a high CAGR of 5.2% through 2033.
What is the demand outlook for dysphagia management?
Demand in the United Kingdom is set to rise at a 2.4% CAGR through 2033.
What was the last 5 years’ CAGR for the dysphagia management business?
The target business exhibited a 1.2% CAGR from 2018 to 2022.
What is the demand outlook for England?
England will likely hold about 75.7% value share in the United Kingdom in 2033.
How many people in the United Kingdom have dysphagia?
Dysphagia affects around 4 million people in the United Kingdom.
Who is responsible for the management of dysphagia?
Speech-language pathologists, otolaryngologists, gastroenterologists, and neurologists.
Who is the treatment team for dysphagia?
Speech and language therapist, physiotherapist, occupational therapist, dietician, and nursing staff.
Table of Content
1. Executive Summary
1.1. United Kingdom Industry Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Business Overview
2.1. Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Inclusion and Exclusions
3. Key Trends
3.1. Key Trends Impacting Growth
3.2. Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology
4.1.1. Estimated Number of Population Suffering from Dysphagia
4.1.2. Severity Specific Cases of Dysphagia
4.2. International Dysphagia Diet Standardization Initiative Framework
4.3. List of Distributors
4.4. Regulatory Scenario
4.5. Unmet Needs
4.6. PESTLE Analysis
4.7. PORTER Analysis
4.8. Value Chain Analysis
5. Background
5.1. Macro-Economic Factors
5.1.1. United Kingdom GDP Growth Outlook
5.1.2. United Kingdom Healthcare Expenditure
5.1.3. Global Industry Analysis
5.2. Forecast Factors - Relevance & Impact
5.2.1. Historic Growth of Key Players
5.2.2. Entry of Top companies
5.2.3. Increasing Prevalence of Various Cancers
5.2.4. Growing Geriatric Population
5.2.5. Prevalence of Stroke and Neurological Disorders
5.2.6. Increasing Spending on Research and Development
5.2.7. Increasing Awareness Regarding Dysphagia
5.2.8. Advancements in Geriatric Medicine
5.2.9. Increasing Adoption of Home Healthcare
5.3. Key Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Demand (in Volume) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical (Volume) Analysis, 2018 to 2022
6.2. Current and Future (Volume) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Value (US$ Million) Analysis, 2018 to 2022
7.2. Current and Future Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Pricing Break-up
8.2.1. Manufacturer Level Pricing
8.2.2. Distributor Level Pricing
8.3. Asia Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Size (US$ Million) Analysis By Product, 2018 to 2022
9.3. Current and Future Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Drugs (Proton Pump Inhibitors)
9.3.2. Feeding Tubes
9.3.2.1. Naso-gastric Tubes
9.3.2.2. PEG Tubes
9.3.3. Nutritional Solutions
9.3.3.1. Thickeners
9.3.3.2. Beverages
9.3.3.3. Purees
9.3.4. Devices
9.3.4.1. Medical Cups
9.3.4.2. Neuromuscular Electrical Stimulation (NEMS)
9.3.4.3. Tactile-thermal Stimulation (TTS)
9.3.4.4. Pharyngeal Electrical Stimulation (PES)
9.4. Business Attractiveness Analysis By Product
10. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
10.1. Introduction / Key Findings
10.2. Historical Size (US$ Million) Analysis By Indication, 2018 to 2022
10.3. Current and Future Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
10.3.1. Oropharyngeal Dysphagia
10.3.2. Esophageal Dysphagia
10.4. Business Attractiveness Analysis By Indication
11. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022
11.3. Current and Future Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Drug Stores
11.3.4. Specialty Clinics
11.4. Business Attractiveness Analysis By Distribution Channel
12. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Size (US$ Million) Analysis By Region, 2018 to 2022
12.3. Current and Future Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
12.3.1. England
12.3.2. Wales
12.3.3. Scotland
12.3.4. Northern Ireland
12.4. Business Attractiveness Analysis By Region
13. England Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022
13.3. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033
13.3.1. By State
13.3.1.1. Greater London
13.3.1.2. West Midlands
13.3.1.3. Greater Manchester
13.3.1.4. Yorkshire
13.3.1.5. Rest of England
13.3.2. By Product
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Business Attractiveness Analysis
13.4.1. By State
13.4.2. By Product
13.4.3. By Indication
13.4.4. By Distribution Channel
13.5. Drivers and Restraints - Impact Analysis
13.6. State Level Analysis & Forecast
13.6.1. Greater London
13.6.1.1. Introduction
13.6.1.2. Industry Analysis and Forecast by Business Taxonomy
13.6.1.2.1. By Product
13.6.1.2.2. By Indication
13.6.1.2.3. By Distribution Channel
13.6.2. West Midlands
13.6.2.1. Introduction
13.6.2.2. Industry Analysis and Forecast by Business Taxonomy
13.6.2.2.1. By Product
13.6.2.2.2. By Indication
13.6.2.2.3. By Distribution Channel
13.6.3. Greater Manchester
13.6.3.1. Introduction
13.6.3.2. Industry Analysis and Forecast by Business Taxonomy
13.6.3.2.1. By Product
13.6.3.2.2. By Indication
13.6.3.2.3. By Distribution Channel
13.6.4. Yorkshire
13.6.4.1. Introduction
13.6.4.2. Industry Analysis and Forecast by Business Taxonomy
13.6.4.2.1. By Product
13.6.4.2.2. By Indication
13.6.4.2.3. By Distribution Channel
13.6.5. Others
13.6.5.1. Introduction
13.6.5.2. Industry Analysis and Forecast by Business Taxonomy
13.6.5.2.1. By Product
13.6.5.2.2. By Indication
13.6.5.2.3. By Distribution Channel
14. Wales Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033
14.3.1. By State
14.3.1.1. Cardiff
14.3.1.2. Swansea
14.3.1.3. Rhondda Cynon Taf
14.3.1.4. Carmarthenshire
14.3.1.5. Rest of Wales
14.3.2. By Product
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Business Attractiveness Analysis
14.4.1. By State
14.4.2. By Product
14.4.3. By Indication
14.4.4. By Distribution Channel
14.5. Drivers and Restraints - Impact Analysis
14.6. State Level Analysis & Forecast
14.6.1. Cardiff
14.6.1.1. Introduction
14.6.1.2. Industry Analysis and Forecast by Business Taxonomy
14.6.1.2.1. By Product
14.6.1.2.2. By Indication
14.6.1.2.3. By Distribution Channel
14.6.2. Swansea
14.6.2.1. Introduction
14.6.2.2. Industry Analysis and Forecast by Business Taxonomy
14.6.2.2.1. By Product
14.6.2.2.2. By Indication
14.6.2.2.3. By Distribution Channel
14.6.3. Rhondda Cynon Taf
14.6.3.1. Introduction
14.6.3.2. Industry Analysis and Forecast by Business Taxonomy
14.6.3.2.1. By Product
14.6.3.2.2. By Indication
14.6.3.2.3. By Distribution Channel
14.6.4. Carmarthenshire
14.6.4.1. Introduction
14.6.4.2. Industry Analysis and Forecast by Business Taxonomy
14.6.4.2.1. By Product
14.6.4.2.2. By Indication
14.6.4.2.3. By Distribution Channel
15. Scotland Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022
15.4. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033
15.4.1. By State
15.4.1.1. Glasgow
15.4.1.2. Edinburgh
15.4.1.3. Aberdeen
15.4.1.4. Lanarkshire
15.4.1.5. Rest of Scotland
15.4.2. By Product
15.4.3. By Indication
15.4.4. By Distribution Channel
15.5. Business Attractiveness Analysis
15.5.1. By State
15.5.2. By Product
15.5.3. By Indication
15.5.4. By Distribution Channel
15.6. Drivers and Restraints - Impact Analysis
15.7. State Level Analysis & Forecast
15.7.1. Glasgow
15.7.1.1. Introduction
15.7.1.2. Industry Analysis and Forecast by Business Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Indication
15.7.1.2.3. By Distribution Channel
15.7.2. Edinburgh
15.7.2.1. Introduction
15.7.2.2. Industry Analysis and Forecast by Business Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Indication
15.7.2.2.3. By Distribution Channel
15.7.3. Aberdeen
15.7.3.1. Introduction
15.7.3.2. Industry Analysis and Forecast by Business Taxonomy
15.7.3.2.1. By Product
15.7.3.2.2. By Indication
15.7.3.2.3. By Distribution Channel
15.7.4. Lanarkshire
15.7.4.1. Introduction
15.7.4.2. Industry Analysis and Forecast by Business Taxonomy
15.7.4.2.1. By Product
15.7.4.2.2. By Indication
15.7.4.2.3. By Distribution Channel
16. North Ireland Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033
16.3.1. By State
16.3.1.1. Antrim
16.3.1.2. Armagh
16.3.1.3. Down
16.3.1.4. Fermanagh
16.3.1.5. Rest of Northern Ireland
16.3.2. By Product
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Business Attractiveness Analysis
16.4.1. By State
16.4.2. By Product
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Drivers and Restraints - Impact Analysis
16.6. State Level Analysis & Forecast
16.6.1. Antrim
16.6.1.1. Introduction
16.6.1.2. Industry Analysis and Forecast by Business Taxonomy
16.6.1.2.1. By Product
16.6.1.2.2. By Indication
16.6.1.2.3. By Distribution Channel
16.6.2. Armagh
16.6.2.1. Introduction
16.6.2.2. Industry Analysis and Forecast by Business Taxonomy
16.6.2.2.1. By Product
16.6.2.2.2. By Indication
16.6.2.2.3. By Distribution Channel
16.6.3. Down
16.6.3.1. Introduction
16.6.3.2. Industry Analysis and Forecast by Business Taxonomy
16.6.3.2.1. By Product
16.6.3.2.2. By Indication
16.6.3.2.3. By Distribution Channel
16.6.4. Fermanagh
16.6.4.1. Introduction
16.6.4.2. Industry Analysis and Forecast by Business Taxonomy
16.6.4.2.1. By Product
16.6.4.2.2. By Indication
16.6.4.2.3. By Distribution Channel
17. Structure Analysis
17.1. Industry Analysis by Tier of Companies
17.2. Business Share Analysis of Top Players
17.3. Presence Analysis
17.3.1. Regional footprint of Players
17.3.2. Product Footprint by Players
17.3.3. Channel footprint by Players
18. Competition Analysis
18.1. Competition Benchmarking
18.2. Branding and Promotional Strategies, By Key Players
18.3. Competition Dashboard
18.4. Key Development Analysis
18.5. Competition Deep Dive
18.5.1. Abbott
18.5.1.1. Overview
18.5.1.2. Product Portfolio
18.5.1.3. Key Financials
18.5.1.4. Sales Footprint
18.5.1.5. SWOT Analysis
18.5.1.6. Key Developments
18.5.1.7. Strategy Overview
18.5.1.7.1. Channel Strategy
18.5.1.7.2. Product Strategy
18.5.1.7.3. Business Strategy
18.5.2. Kent Precision Foods Group
18.5.2.1. Overview
18.5.2.2. Product Portfolio
18.5.2.3. Key Financials
18.5.2.4. Sales Footprint
18.5.2.5. SWOT Analysis
18.5.2.6. Key Developments
18.5.2.7. Strategy Overview
18.5.2.7.1. Channel Strategy
18.5.2.7.2. Product Strategy
18.5.2.7.3. Business Strategy
18.5.3. Nestlé Health Science
18.5.3.1. Overview
18.5.3.2. Product Portfolio
18.5.3.3. Key Financials
18.5.3.4. Sales Footprint
18.5.3.5. SWOT Analysis
18.5.3.6. Key Developments
18.5.3.7. Strategy Overview
18.5.3.7.1. Channel Strategy
18.5.3.7.2. Product Strategy
18.5.3.7.3. Business Strategy
18.5.4. Danone S.A
18.5.4.1. Overview
18.5.4.2. Product Portfolio
18.5.4.3. Key Financials
18.5.4.4. Sales Footprint
18.5.4.5. SWOT Analysis
18.5.4.6. Key Developments
18.5.4.7. Strategy Overview
18.5.4.7.1. Channel Strategy
18.5.4.7.2. Product Strategy
18.5.4.7.3. Business Strategy
18.5.5. Hormel Foods Corporation
18.5.5.1. Overview
18.5.5.2. Product Portfolio
18.5.5.3. Key Financials
18.5.5.4. Sales Footprint
18.5.5.5. SWOT Analysis
18.5.5.6. Key Developments
18.5.5.7. Strategy Overview
18.5.5.7.1. Channel Strategy
18.5.5.7.2. Product Strategy
18.5.5.7.3. Business Strategy
18.5.6. Fresenius Kabi AG
18.5.6.1. Overview
18.5.6.2. Product Portfolio
18.5.6.3. Key Financials
18.5.6.4. Sales Footprint
18.5.6.5. SWOT Analysis
18.5.6.6. Key Developments
18.5.6.7. Strategy Overview
18.5.6.7.1. Channel Strategy
18.5.6.7.2. Product Strategy
18.5.6.7.3. Business Strategy
18.5.7. Cipla Ltd
18.5.7.1. Overview
18.5.7.2. Product Portfolio
18.5.7.3. Key Financials
18.5.7.4. Sales Footprint
18.5.7.5. SWOT Analysis
18.5.7.6. Key Developments
18.5.7.7. Strategy Overview
18.5.7.7.1. Channel Strategy
18.5.7.7.2. Product Strategy
18.5.7.7.3. Business Strategy
18.5.8. Eisai Co Ltd
18.5.8.1. Overview
18.5.8.2. Product Portfolio
18.5.8.3. Key Financials
18.5.8.4. Sales Footprint
18.5.8.5. SWOT Analysis
18.5.8.6. Key Developments
18.5.8.7. Strategy Overview
18.5.8.7.1. Channel Strategy
18.5.8.7.2. Product Strategy
18.5.8.7.3. Business Strategy
18.5.9. Becton, Dickinson and Company (BD)
18.5.9.1. Overview
18.5.9.2. Product Portfolio
18.5.9.3. Key Financials
18.5.9.4. Sales Footprint
18.5.9.5. SWOT Analysis
18.5.9.6. Key Developments
18.5.9.7. Strategy Overview
18.5.9.7.1. Channel Strategy
18.5.9.7.2. Product Strategy
18.5.9.7.3. Business Strategy
18.5.10. Cook Medical Inc.
18.5.10.1. Overview
18.5.10.2. Product Portfolio
18.5.10.3. Key Financials
18.5.10.4. Sales Footprint
18.5.10.5. SWOT Analysis
18.5.10.6. Key Developments
18.5.10.7. Strategy Overview
18.5.10.7.1. Channel Strategy
18.5.10.7.2. Product Strategy
18.5.10.7.3. Business Strategy
18.5.11. AstraZeneca Plc.
18.5.11.1. Overview
18.5.11.2. Product Portfolio
18.5.11.3. Key Financials
18.5.11.4. Sales Footprint
18.5.11.5. SWOT Analysis
18.5.11.6. Key Developments
18.5.11.7. Strategy Overview
18.5.11.7.1. Channel Strategy
18.5.11.7.2. Product Strategy
18.5.11.7.3. Business Strategy
18.5.12. VitalStim UK
18.5.12.1. Overview
18.5.12.2. Product Portfolio
18.5.12.3. Key Financials
18.5.12.4. Sales Footprint
18.5.12.5. SWOT Analysis
18.5.12.6. Key Developments
18.5.12.7. Strategy Overview
18.5.12.7.1. Channel Strategy
18.5.12.7.2. Product Strategy
18.5.12.7.3. Business Strategy
18.5.13. Nutricia Limited
18.5.13.1. Overview
18.5.13.2. Product Portfolio
18.5.13.3. Key Financials
18.5.13.4. Sales Footprint
18.5.13.5. SWOT Analysis
18.5.13.6. Key Developments
18.5.13.7. Strategy Overview
18.5.13.7.1. Channel Strategy
18.5.13.7.2. Product Strategy
18.5.13.7.3. Business Strategy
18.5.14. Simply Food Solutions Limited
18.5.14.1. Overview
18.5.14.2. Product Portfolio
18.5.14.3. Key Financials
18.5.14.4. Sales Footprint
18.5.14.5. SWOT Analysis
18.5.14.6. Key Developments
18.5.14.7. Strategy Overview
18.5.14.7.1. Channel Strategy
18.5.14.7.2. Product Strategy
18.5.14.7.3. Business Strategy
18.5.15. Ampcare, LLC
18.5.15.1. Overview
18.5.15.2. Product Portfolio
18.5.15.3. Key Financials
18.5.15.4. Sales Footprint
18.5.15.5. SWOT Analysis
18.5.15.6. Key Developments
18.5.15.7. Strategy Overview
18.5.15.7.1. Channel Strategy
18.5.15.7.2. Product Strategy
18.5.15.7.3. Business Strategy
18.5.16. E2 Scientific Corp
18.5.16.1. Overview
18.5.16.2. Product Portfolio
18.5.16.3. Key Financials
18.5.16.4. Sales Footprint
18.5.16.5. SWOT Analysis
18.5.16.6. Key Developments
18.5.16.7. Strategy Overview
18.5.16.7.1. Channel Strategy
18.5.16.7.2. Product Strategy
18.5.16.7.3. Business Strategy
18.5.17. TheraSIP LLC
18.5.17.1. Overview
18.5.17.2. Product Portfolio
18.5.17.3. Key Financials
18.5.17.4. Sales Footprint
18.5.17.5. SWOT Analysis
18.5.17.6. Key Developments
18.5.17.7. Strategy Overview
18.5.17.7.1. Channel Strategy
18.5.17.7.2. Product Strategy
18.5.17.7.3. Business Strategy
18.5.18. Phagenesis
18.5.18.1. Overview
18.5.18.2. Product Portfolio
18.5.18.3. Key Financials
18.5.18.4. Sales Footprint
18.5.18.5. SWOT Analysis
18.5.18.6. Key Developments
18.5.18.7. Strategy Overview
18.5.18.7.1. Channel Strategy
18.5.18.7.2. Product Strategy
18.5.18.7.3. Business Strategy
18.5.19. ProvaMed®
18.5.19.1. Overview
18.5.19.2. Product Portfolio
18.5.19.3. Key Financials
18.5.19.4. Sales Footprint
18.5.19.5. SWOT Analysis
18.5.19.6. Key Developments
18.5.19.7. Strategy Overview
18.5.19.7.1. Channel Strategy
18.5.19.7.2. Product Strategy
18.5.19.7.3. Business Strategy
19. Assumptions and Acronyms Used20. Research Methodology
List of Tables
Table 01: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 02: Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 03: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 04: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 05: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Region
Table 06: England Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 07: England Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 08: England Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 09: England Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 10: England Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 11: Wales Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 12: Wales Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 13: Wales Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 14: Wales Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 15: Wales Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 16: Scotland Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 17: Scotland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 18: Scotland Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 19: Scotland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 20: Scotland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 21: Northern Ireland Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 22: Northern Ireland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 23: Northern Ireland Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 24: Northern Ireland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 25: Northern Ireland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
List of Charts
Figure 01: Volume (Units), 2018 to 2022
Figure 02: Volume (Units) & Y-o-Y Growth (%) Analysis, 2023 to 2033
Figure 03: Dysphagia Management, Pricing Analysis per unit (US$), in 2023
Figure 04: Dysphagia Management, Pricing Forecast per unit (US$), in 2033
Figure 05: Value (US$ Million) Analysis, 2018 to 2022
Figure 06: Business Forecast & Y-o-Y Growth, 2023 to 2033
Figure 07: Absolute $ Opportunity (US$ Million) Analysis, 2023 to 2033
Figure 08: Value Share (%) Analysis 2023 and 2033, by Product
Figure 09: Y-o-Y Growth (%) Analysis 2023 to 2033, by Product
Figure 10: Business Attractiveness Analysis 2023 to 2033, by Product
Figure 11: Value Share (%) Analysis 2023 and 2033, by Indication
Figure 12: Y-o-Y Growth (%) Analysis 2023 to 2033, by Indication
Figure 13: Business Attractiveness Analysis 2023 to 2033, by Indication
Figure 14: Value Share (%) Analysis 2023 and 2033, by Distribution Channel
Figure 15: Y-o-Y Growth (%) Analysis 2023 to 2033, by Distribution Channel
Figure 16: Business Attractiveness Analysis 2023 to 2033, by Distribution Channel
Figure 17: Value Share (%) Analysis 2023 and 2033, by Region
Figure 18: Y-o-Y Growth (%) Analysis 2023 to 2033, by Region
Figure 19: Business Attractiveness Analysis 2023 to 2033, by Region
Figure 20: England Value (US$ Million) Analysis, 2018 to 2022
Figure 21: England Value (US$ Million) Forecast, 2023 to 2033
Figure 22: England Value Share, by Product (2023 E)
Figure 23: England Value Share, by Indication (2023 E)
Figure 24: England Value Share, by Distribution Channel (2023 E)
Figure 25: England Value Share, by Country (2023 E)
Figure 26: England Business Attractiveness Analysis by Product, 2023 to 2033
Figure 27: England Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 28: England Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 29: England Business Attractiveness Analysis by Country, 2023 to 2033
Figure 30: Greater London Value Proportion Analysis, 2022
Figure 31: Global Vs. Greater London Growth Comparison
Figure 32: Greater London Business Share Analysis (%) by Product, 2022 & 2033
Figure 33: Greater London Business Share Analysis (%) by Indication, 2022 & 2033
Figure 34: Greater London Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 35: West Midlands Value Proportion Analysis, 2022
Figure 36: Global Vs. West Midlands. Growth Comparison
Figure 37: West Midlands Business Share Analysis (%) by Product, 2022 & 2033
Figure 38: West Midlands Business Share Analysis (%) by Indication, 2022 & 2033
Figure 39: West Midlands Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 40: Global Vs. Greater Manchester. Growth Comparison
Figure 41: Greater Manchester Business Share Analysis (%) by Product, 2022 & 2033
Figure 42: Greater Manchester Business Share Analysis (%) by Indication, 2022 & 2033
Figure 43: Greater Manchester Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 44: Global Vs. Yorkshire. Growth Comparison
Figure 45: Yorkshire Business Share Analysis (%) by Product, 2022 & 2033
Figure 46: Yorkshire Business Share Analysis (%) by Indication, 2022 & 2033
Figure 47: Yorkshire Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 48: Global Vs. Rest of England. Growth Comparison
Figure 49: Rest of England Business Share Analysis (%) by Product, 2022 & 2033
Figure 50: Rest of England Business Share Analysis (%) by Indication, 2022 & 2033
Figure 51: Rest of England Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 52: Wales Value (US$ Million) Analysis, 2018 to 2022
Figure 53: Wales Value (US$ Million) Forecast, 2023 to 2033
Figure 54: Wales Value Share, by Product (2023 E)
Figure 55: Wales Value Share, by Indication (2023 E)
Figure 56: Wales Value Share, by Distribution Channel (2023 E)
Figure 57: Wales Value Share, by Country (2023 E)
Figure 58: Wales Business Attractiveness Analysis by Product, 2023 to 2033
Figure 59: Wales Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 60: Wales Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 61: Wales Business Attractiveness Analysis by Country, 2023 to 2033
Figure 62: Cardiff Value Proportion Analysis, 2022
Figure 63: Global Vs Cardiff Growth Comparison
Figure 64: Cardiff Business Share Analysis (%) by Product, 2022 & 2033
Figure 65: Cardiff Business Share Analysis (%) by Indication, 2022 & 2033
Figure 66: Cardiff Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 67: Swansea Value Proportion Analysis, 2022
Figure 68: Global Vs. Swansea. Growth Comparison
Figure 69: Swansea Business Share Analysis (%) by Product, 2022 & 2033
Figure 70: Swansea Business Share Analysis (%) by Indication, 2022 & 2033
Figure 71: Swansea Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 72: Rhondda Cynon Taf Value Proportion Analysis, 2022
Figure 73: Global Vs Rhondda Cynon Taf Growth Comparison
Figure 74: Rhondda Cynon Taf Business Share Analysis (%) by Product, 2022 & 2033
Figure 75: Rhondda Cynon Taf Business Share Analysis (%) by Indication, 2022 & 2033
Figure 76: Rhondda Cynon Taf Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 77: Carmarthenshire Value Proportion Analysis, 2022
Figure 78: Global Vs Carmarthenshire Growth Comparison
Figure 79: Carmarthenshire Business Share Analysis (%) by Product, 2022 & 2033
Figure 80: Carmarthenshire Business Share Analysis (%) by Indication, 2022 & 2033
Figure 81: Carmarthenshire Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 82: Rest of Wales Value Proportion Analysis, 2022
Figure 83: Global Vs Rest of Wales Growth Comparison
Figure 84: Rest of Wales Business Share Analysis (%) by Product, 2022 & 2033
Figure 85: Rest of Wales Business Share Analysis (%) by Indication, 2022 & 2033
Figure 86: Rest of Wales Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 87: Scotland Value (US$ Million) Analysis, 2018 to 2022
Figure 88: Scotland Value (US$ Million) Forecast, 2023 to 2033
Figure 89: Scotland Value Share, by Product (2023 E)
Figure 99: Scotland Value Share, by Indication (2023 E)
Figure 100: Scotland Value Share, by Distribution Channel (2023 E)
Figure 101: Scotland Value Share, by Country (2023 E)
Figure 102: Scotland Business Attractiveness Analysis by Product, 2023 to 2033
Figure 103: Scotland Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 104: Scotland Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 105: Scotland Business Attractiveness Analysis by Country, 2023 to 2033
Figure 106: Glasgow Value Proportion Analysis, 2022
Figure 107: Global Vs. Glasgow Growth Comparison
Figure 108: Glasgow Business Share Analysis (%) by Product, 2022 & 2033
Figure 109: Glasgow Business Share Analysis (%) by Indication, 2022 & 2033
Figure 110: Glasgow Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 111: Edinburgh Value Proportion Analysis, 2022
Figure 112: Global Vs. Edinburgh Growth Comparison
Figure 113: Edinburgh Business Share Analysis (%) by Product, 2022 & 2033
Figure 114: Edinburgh Business Share Analysis (%) by Indication, 2022 & 2033
Figure 115: Edinburgh Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 116: Aberdeen Value Proportion Analysis, 2022
Figure 117: Global Vs. Aberdeen Growth Comparison
Figure 118: Aberdeen Business Share Analysis (%) by Product, 2022 & 2033
Figure 119: Aberdeen Business Share Analysis (%) by Indication, 2022 & 2033
Figure 120: Aberdeen Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 121: Lanarkshire Value Proportion Analysis, 2022
Figure 122: Global Vs Lanarkshire Growth Comparison
Figure 123: Lanarkshire Business Share Analysis (%) by Product, 2022 & 2033
Figure 124: Lanarkshire Business Share Analysis (%) by Indication, 2022 & 2033
Figure 125: Lanarkshire Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 126: Rest of Scotland Value Proportion Analysis, 2022
Figure 127: Global Vs Rest of Scotland Growth Comparison
Figure 128: Rest of Scotland Business Share Analysis (%) by Product, 2022 & 2033
Figure 129: Rest of Scotland Business Share Analysis (%) by Indication, 2022 & 2033
Figure 130: Rest of Scotland Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 131: Northern Ireland Value (US$ Million) Analysis, 2018 to 2022
Figure 132: Northern Ireland Value (US$ Million) Forecast, 2023 to 2033
Figure 133: Northern Ireland Value Share, by Product (2023 E)
Figure 134: Northern Ireland Value Share, by Indication (2023 E)
Figure 135: Northern Ireland Value Share, by Distribution Channel (2023 E)
Figure 136: Northern Ireland Value Share, by Country (2023 E)
Figure 137: Northern Ireland Business Attractiveness Analysis by Product, 2023 to 2033
Figure 138: Northern Ireland Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 139: Northern Ireland Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 140: Northern Ireland Business Attractiveness Analysis by Country, 2023 to 2033
Figure 141: Antrim Value Proportion Analysis, 2022
Figure 142: Global Vs. Antrim Growth Comparison
Figure 143: Antrim Business Share Analysis (%) by Product, 2022 & 2033
Figure 144: Antrim Business Share Analysis (%) by Indication, 2022 & 2033
Figure 145: Antrim Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 146: Armagh Value Proportion Analysis, 2022
Figure 147: Global Vs. Armagh Growth Comparison
Figure 148: Armagh Business Share Analysis (%) by Product, 2022 & 2033
Figure 149: Armagh Business Share Analysis (%) by Indication, 2022 & 2033
Figure 150: Armagh Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 151: Down Value Proportion Analysis, 2022
Figure 152: Global Vs. Down Growth Comparison
Figure 153: Down Business Share Analysis (%) by Product, 2022 & 2033
Figure 154: Down Business Share Analysis (%) by Indication, 2022 & 2033
Figure 155: Down Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 156: Fermanagh Value Proportion Analysis, 2022
Figure 157: Global Vs. Fermanagh Growth Comparison
Figure 158: Fermanagh Business Share Analysis (%) by Product, 2022 & 2033
Figure 159: Fermanagh Business Share Analysis (%) by Indication, 2022 & 2033
Figure 160: Fermanagh Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 161: Rest of Northern Ireland Value Proportion Analysis, 2022
Figure 162: Global Vs. Rest of Northern Ireland Growth Comparison
Figure 163: Rest of Northern Ireland Business Share Analysis (%) by Product, 2022 & 2033
Figure 164: Rest of Northern Ireland Business Share Analysis (%) by Indication, 2022 & 2033
Figure 165: Rest of Northern Ireland Business Share Analysis (%) by Distribution Channel, 2022 & 2033
